Please enable javascript in your browser to view this page correctly

You need to upgrade your Flash Player
Tuesday, February 7, 2012

Overview of treatment of PAH

Recommendation Level of Evidence Net Benefit Grade of Recommendation
Calcium Channel blockers
Acute responders to vasoreactivity testing, defined as fall in mean PAP ≥ 10mmHG to ≤ 40mmHg with increased or unchanged cardiac output and absence of right heart failure may be treated with oral CCBs, with careful reassessment
1. Idiopathic PAH
2. Secondary PAH from underlying conditions




low
expert opinion





substantial
intermediate





B
E/B
Sildenafil
Patients who are not candidates or in whom CCB therapy has failed can initiate long term therapy for the following functional class:
1. II or III
2. IV



Good
Low



Substantial
Intermediate



A
C

For the complete table please download the pdf file at the top.

Copyright © saudithoracic 2008 All Rights Reserved